Provider review
Bliv Review: Four Entry Prices, One Page, and a Pharmacy It Only Names in the Consent Form
Bliv publishes four different “as low as” figures on one page — a hero rate, a semaglutide rate, a tirzepatide rate and a financing rate — and not one of them is the price of anything you can put in a cart. It does name the pharmacy that fills the prescription, which most of this category will not do. It names it on the telehealth consent form, three clicks from where anyone chooses a plan.
Correction, August 2026
This review previously said: “Bliv makes no efficacy claim at all — and also names no pharmacy, states no license, publishes no test result and has no pricing page.”
That was wrong. Two of those four were absence claims, and absence claims are the ones that rot. On the efficacy half, the site now carries outcome copy the August read did not describe — "a proven GLP-1 option for steady weight loss", a BMI widget that projects a pound figure, twenty-three named testimonials, and an intake screen reading "Bliv customers report losing up to 20%+ of their body weight on GLP-1". On the pharmacy half, RedRock Pharmacy is named with a street address and a phone number at the foot of the telehealth consent form. We cannot tell you whether that paragraph is new or whether the original sweep simply never opened the consent form, and either answer would be a guess — but the lesson is the checkable one: a pharmacy name in this market turns up in the consent, the shipping policy or the refund policy far more often than on a product page, and an absence claim that has not read those documents has not been tested.
It now says: Re-read and re-walked 2026-08-26. Bliv does make efficacy claims, and the largest of them — up to 20%+ of body weight — reaches past semaglutide's phase 3 mean of about 14.9%; that row is now graded "overstates" rather than "matches". Bliv does name its pharmacy: RedRock Pharmacy, 450 South 900 East, Suite 150, SLC, UT 84102, (801) 433-9500, on the telehealth consent form. Two of the four findings stand unchanged: no regulatory category is stated anywhere, and no test result of any kind is published. The pricing finding is narrowed — there is still no separate pricing page, because /pricing, /faq and /semaglutide all serve the same single URL, but that page now carries three priced plan cards, so the review no longer says no price structure is published.
Names its pharmacy in the consent form, quotes four different entry prices on one page, and puts its biggest weight-loss number where only someone already in the intake will see it.
Worth trusting if
- You want the lowest-friction intake in this category — no phone call, no video visit, and a stated approval turnaround of about a day
- You want the pharmacy named before you pay, and will read the telehealth consent form to find it
- You are financing, because pay-later is priced as its own plan rather than folded into the headline
Be skeptical if
- You want to know which of the four published figures applies to you before starting an intake
- An open FDA warning letter would stop you buying
- You are relying on “no hidden subscriptions”, because the terms describe automatic recurring billing and a membership fee that is non-refundable after 72 hours
Compounded only
Phase 3 trials
Named
February 2026
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens joinbliv.com. A link is not a recommendation to take anything.
Provenance
What Bliv actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded GLP-1 injection — $116 a month, hedged as “as low as” and footnoted “based on plan structure and eligibility” (read 2026-08-26; on 2026-08-14 this review recorded $116 as a pay-later installment rather than as the semaglutide rate). Tirzepatide is $199. Neither figure is a checkout total, and the same page also quotes $58 in the hero and $29 for financing.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to Bliv.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Bliv’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded GLP-1 injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“Semaglutide — A proven GLP-1 option for steady weight loss. *as low as $116 per month · Helps you feel full faster · Reduces cravings · Great starting option · Gradual dose increases. * based on plan structure and eligibility […] Bliv customers report losing up to 20%+ of their body weight on GLP-1. […] Medications prescribed through Bliv are compounded and dispensed by licensed U.S. pharmacies pursuant to a valid prescription.”
Read on the Bliv site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — mean weight change −14.9% against −2.4% on placebo. The record for the FDA-approved product, and the ceiling a semaglutide claim has to sit under.
Bliv cites no trial, publication or registry identifier anywhere on its site, checked 2026-08-26 across the single page it serves at /get-a-glp-1-prescription, the eleven FAQ answers opened one by one, the terms, the refund policy and the telehealth consent form. Its efficacy figures are attributed to its own customers rather than to any study, and no method, cohort size, time point or drop-out figure is given for them.
Re-read 2026-08-26, and this row is graded the opposite way round from how it was published on 14 August — see the correction at the top of the page. Bliv now makes outcome claims, and the biggest of them reaches past the trial it is attached to. "Bliv customers report losing up to 20%+ of their body weight on GLP-1" appears on the third screen of the walked intake, before a patient has chosen a medication, and a full screen further on reads "Lose up to 20% of your body weight." Semaglutide's phase 3 mean is about 14.9% over 68 weeks; 20%+ is the tirzepatide end of the market, and neither figure was produced by a compounded preparation. The attribution is to "Bliv customers", which is the honest form of an outcome claim in principle — but no cohort size, time point, method or drop-out rate is published, and "up to 20%+" is not a mean, so there is nothing behind the sentence a reader could weigh. "A proven GLP-1 option" does the same work more quietly: what is proven is Wegovy, and what is sold here is a compounded copy of it.1
Dispensing chain
Who actually fills your prescription
- RedRock Pharmacy, 450 South 900 East, Suite 150, Salt Lake City, UT 84102, (801) 433-9500
Read the full account
Bliv names the pharmacy, with a street address and a phone number — and it does so in the one place almost nobody reads. The telehealth consent form ends: "Pharmacy Contact: RedRock Pharmacy · 450 South 900 East, Suite 150, SLC, UT 84102 · (801) 433-9500." That is a checkable disclosure and it deserves credit; an earlier version of this review said no pharmacy was named anywhere, which was wrong, and the correction is at the top of the page. What is missing is everything around it. No regulatory category is stated — the strings "503A" and "503B" do not appear on any Bliv page checked on 2026-08-26. No product page or plan card mentions RedRock; the marketing badge says only "US-BASED PHARMACY", and the one substantive supply-chain sentence, at the foot of the single page the site serves, reads "Medications prescribed through Bliv are compounded and dispensed by licensed U.S. pharmacies pursuant to a valid prescription" — pharmacies, plural, unnamed. The same consent form also tells a patient they "may select the pharmacy of his or her choosing if the doctor issues a prescription", which sits oddly beside a named partner. So a buyer is given a name, in a document they sign rather than on the page where they choose, and is not told whether that named pharmacy is the one that will fill their order.
Read on the Bliv site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency result, purity result, sterility standard, named laboratory or testing statement of any kind appears on the site, checked 2026-08-26 across the single served page, the eleven expanded FAQ answers, the terms, the refund policy, the HIPAA policy and the telehealth consent form. The nearest thing to a quality statement is the badge "US-BASED PHARMACY", which is a claim about geography. There is now a pharmacy to ask — RedRock Pharmacy, named on the consent form with a phone number — which is more than this review could say in August.
Read on the Bliv site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
No state list or set of exclusions is published. The intake opens with a state selector — "Select the state you live in… we will deliver your medication to if prescribed" — so eligibility is settled inside the flow rather than on any page a reader can check first.
Read the full licensing claim
Get a GLP-1 Prescription Online | No Calls, No Video
Read on the Bliv site, August 2026.
Regulatory
The FDA warning letter
Issued February 2026
Bliv Wellness LLC dba Bliv — MARCS-CMS 721479. Concerns marketing and labeling.
Read the full allegation
FDA reviewed the website at https://www.joinbliv.com in December 2025 and cited its representations as false or misleading under FD&C Act sections 502(a) and 502(bb). The letter's single finding: "The compounded semaglutide and tirzepatide products displayed on your website identify 'Bliv' on the pictured label, suggesting Bliv is the compounder of those drugs when in fact it is not." It quotes no advertising copy, makes no allegation about sterility, potency, contamination or any other product-quality matter, and states its citations are "not intended to be an all-inclusive statement of violations."
What has changed since
Re-fetched from fda.gov on 2026-08-26: the letter is still published and its text is unchanged. The site itself has changed a good deal since December 2025 — it now carries outcome claims it did not carry when this review was first written, and it names RedRock Pharmacy on the telehealth consent form. Whether the pictured labels the letter objected to have changed is not something a reader of the marketing pages can determine, and this review does not assert it either way.
We did this ourselves
What happens when you sign up with Bliv
We went through Bliv’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Meet the prices first. Three plan cards sit on the homepage, above the fold on a second scroll, before any question is asked.
- Choose the state the medication would ship to, and tick the terms and telehealth consent. The state field is the first thing the flow gates on.
- Say what your weight-loss goal is, then read a screen reporting that 83% of Americans are seeking a weight they feel comfortable in.
- Say how much you want to lose. This screen carries the largest claim on the walk: that Bliv customers report losing up to 20%+ of their body weight.
- Pick semaglutide, tirzepatide or "not sure".
- Read a screen headed "Lose up to 20% of your body weight", then give your date of birth.
- Answer what reaching your goal weight would mean to you, then scroll a wall of twenty-three named before-and-after testimonials with pound counts.
- The flow then asks for a first name, last name, email, phone number and a password. That is an account, and the walk stopped there.
- Four different entry figures appear on the one page the site serves: $58 in the hero, $116 on the semaglutide card, $199 on the tirzepatide card and $29 on the pay-later card. Every one is hedged “as low as” and footnoted “based on plan structure and eligibility”.
- $116 does double duty. It is the semaglutide card's own monthly rate, and it is also the figure in the financing sentence “Pay later eligible, with options starting around $116/month and no hidden subscriptions.”
- No price appears at any point inside the intake. Ten screens in, the flow asks for an account with a password before showing one — so the figures on the homepage are the only figures a prospective buyer ever sees.
- The walk is partial in as many words: it stopped at the account-creation screen at /quiz/sign-in, which asks for a password. No account was created, no medical questionnaire past the goal questions was answered, and nothing was bought.
- The pharmacy is named, but not here. RedRock Pharmacy appears on the telehealth consent form linked from the footer, with an address and a phone number; nothing in the eight-step flow mentions it.
- "NO CONTRACTS" and "no hidden subscriptions" run on the site's own badge bar. The terms of service describe automatic recurring payments that "will automatically renew for an additional period unless cancelled prior to the next billing period".
- Refunds are narrower than the badges suggest: a full refund only within 72 hours of purchase and only if medication has not gone to the pharmacy, $24.99 charged for a provider consultation, and if a policy change stops Bliv supplying a medication the money becomes account credit rather than a refund.
- The eleven FAQ answers are collapsed but real — each one opens to a full answer in the page, so a search engine and a reader see the same text. They are all side-effect management; none of them is about price, pharmacy or cancellation.
Bliv support
- Phone
- 888-859-2882
- support@joinbliv.com
Assessment
What holds up, and what does not
- It names the pharmacy that fills the prescription — RedRock Pharmacy, with a street address and a phone number — which most of this category will not do at all.
- The intake is genuinely low-friction: no phone call, no video visit, and a stated approval turnaround of about a day.
- The operating company is named and locatable: Bliv Wellness LLC, 2411 Kiesel Ave. Ste 402, Ogden, UT 84401.
Show 4 more
- A phone number and an email are published in the footer of every page, and a live-agent text link runs through the whole intake.
- Its own copy states plainly that medications "are compounded and dispensed by licensed U.S. pharmacies pursuant to a valid prescription" rather than implying a manufactured product.
- The eleven FAQ answers are rendered in the page rather than hidden behind script, so what a reader sees is what a search engine sees.
- The state a patient lives in is the first thing the intake asks, before any health question.
- "Bliv customers report losing up to 20%+ of their body weight on GLP-1" appears inside the intake, attached to no cohort size, no time point and no method — and above semaglutide's phase 3 mean of about 14.9%.
- The largest claims are all past the front door: the 20% screens and the testimonial wall are inside the flow, where a reader comparing sellers will not see them.
- Four entry prices on one page — $58, $116, $199 and $29 — every one hedged “as low as”, and none of them a total anyone can be charged.
Show 7 more
- No regulatory category is stated anywhere. "503A" and "503B" appear on no Bliv page.
- No certificate of analysis, potency result or testing statement of any kind is published, and the named pharmacy is named nowhere near a product.
- There is still no separate pricing page — /pricing, /faq, /semaglutide and the bare domain all serve the same single URL.
- "NO CONTRACTS" and "no hidden subscriptions" sit on the badge bar while the terms describe subscriptions that renew automatically until canceled.
- The refund window is 72 hours, the membership fee is non-refundable after it, a $24.99 consultation fee applies, and a supply failure produces account credit rather than money back.
- No state coverage list or exclusions are published; the intake is the only way to find out.
- An open FDA warning letter (721479, February 2026) is on file against Bliv Wellness LLC.
Verdict
The bottom line
Bliv will tell you who compounds your medication — RedRock Pharmacy, address and phone number, on the telehealth consent form — and that is worth more than most of this market offers. What it will not tell you is which of its four advertised prices is yours, on what cycle it renews, or where the 20% figure inside its intake came from. Read the consent form and the refund policy before the card goes on file; both say more than the plan cards do.
Opens joinbliv.com. A link is not a recommendation to take anything.
Four prices, one page
Bliv serves one page. /pricing, /faq, /semaglutide and the bare domain all resolve to `/get-a-glp-1-prescription`, checked by navigation on 26 August 2026 — the "Pricing" link in the navigation is an anchor to a section of the page you are already on.
That page quotes four entry figures:
| Where it appears | Figure | What it is | |---|---|---| | Hero | $58/mo | "Starting as low as" — attached to no product | | Semaglutide card | $116/mo | "*as low as", "based on plan structure and eligibility" | | Tirzepatide card | $199/mo | Same hedges | | Pay Later card | $29/mo | CareCredit 24 months at 0%, or Klarna |
None is a total. Every one carries "as low as" and the footnote "based on plan structure and eligibility", and no plan length, dose band or renewal rate is attached to any of them.
$116 then does a second job further down the same page: "Pay later eligible, with options starting around $116/month and no hidden subscriptions." So the same number is both the medication rate and the financing rate, depending on which section you are reading.
An earlier version of this review read $116 as the financing figure only, and said the site published no price structure at all. Both readings are corrected above.
Full analysis — 5 more sectionsThe pharmacy is named. It is named in the consent form. · What the intake says that the shop window does not · The badges and the terms · The FDA letter · What this means if you are buying
The pharmacy is named. It is named in the consent form.
Here is the thing this review got wrong in August, and it is worth being specific about where the name actually lives.
At the foot of `/telehealth-consent-form`:
"Pharmacy Contact: RedRock Pharmacy · 450 South 900 East, Suite 150, SLC, UT 84102 · (801) 433-9500"
A name, a street address and a phone number. In this market that is a real disclosure, and Bliv gets credit for it.
It is also three clicks from anywhere a person chooses a plan. The plan cards say nothing about a pharmacy. The badge bar says "US-BASED PHARMACY". The only substantive sentence on the page itself reads:
"Medications prescribed through Bliv are compounded and dispensed by licensed U.S. pharmacies pursuant to a valid prescription."
Pharmacies, plural, unnamed. And the same consent form adds that a patient "may select the pharmacy of his or her choosing if the doctor issues a prescription", which leaves it genuinely unclear whether RedRock will be the one that fills your order.
Neither "503A" nor "503B" appears anywhere on the site.
What the intake says that the shop window does not
The signup was walked on 26 August 2026 and stopped at an account-creation screen. Ten screens, no price on any of them, and the two largest claims on the whole property:
"Bliv customers report losing up to 20%+ of their body weight on GLP-1."
"Lose up to 20% of your body weight."
The first sits on the third screen, before a medication has been chosen. The second is a full screen of its own.
Semaglutide's phase 3 mean, from STEP 1, is about 14.9% over 68 weeks. 1 Twenty per cent and above is the tirzepatide end of this market, and no compounded preparation of either molecule has been through a registered trial.
Attributing a figure to your own customers rather than to a trial is, in principle, the honest form of an outcome claim. What is missing here is everything that would let a reader weigh it: how many customers, over what period, measured how, and how many stopped. "Up to 20%+" is not a mean of anything.
Then twenty-three named testimonials with pound counts, and, on the public page, a BMI widget that answers "You could lose: 36 lbs".
The badges and the terms
Three badges run across the top of every page: NO CONTRACTS, PAY LATER OPTIONS, and — in the reasons block — "no hidden subscriptions".
The terms of service, section 7:
"Subscriptions include automatic recurring payments… Subscriptions will automatically renew for an additional period unless cancelled prior to the next billing period."
And the refund policy: a full refund only within 72 hours of purchase and only if medication has not yet gone to the pharmacy; the membership fee non-refundable after that; $24.99 charged for a provider consultation; and if a policy change prevents Bliv supplying a medication, "a credit will be applied to your account… No refunds will be issued."
None of that is unusual for this category. It is unusual to run "no hidden subscriptions" above it.
The FDA letter
Warning letter 721479 was issued to Bliv Wellness LLC on 20 February 2026 and was still published on fda.gov when re-fetched on 26 August 2026.
Its single finding, quoted from the body: the compounded semaglutide and tirzepatide products pictured on the website "identify 'Bliv' on the pictured label, suggesting Bliv is the compounder of those drugs when in fact it is not." The letter alleges nothing about sterility, potency or contamination.
A letter discloses; it does not disqualify. Read it directly on fda.gov rather than relying on any account of it, this one included.
What this means if you are buying
Ask which of the four figures applies to your dose, what it renews at, and on what interval — none of that is published.
Then use the one advantage Bliv gives you that most of its competitors do not: you have a pharmacy name and a phone number. Call RedRock and ask whether they are filling Bliv prescriptions, and ask for the certificate of analysis for the lot you would be shipped. Bliv publishes none.
Questions
Frequently asked questions
Does Bliv say who makes its medication?
Yes — on the telehealth consent form, which is not where most people would look. It ends: "Pharmacy Contact: RedRock Pharmacy, 450 South 900 East, Suite 150, SLC, UT 84102, (801) 433-9500." A name with a street address and a phone number is a real disclosure and most of this category makes none. An earlier version of this review said no pharmacy was named anywhere; that was wrong and the correction is at the top of the page. What is still missing: no plan card or product page mentions RedRock, no regulatory category is stated — "503A" and "503B" appear nowhere on the site — and the same consent form says a patient "may select the pharmacy of his or her choosing", so it is not clear that RedRock is the pharmacy that would fill your order.
What does Bliv claim its GLP-1s do?
More than it used to, and the biggest claim is inside the intake rather than on the shop window. The homepage sells semaglutide as "a proven GLP-1 option for steady weight loss" that "helps you feel full faster" and "reduces cravings", and a BMI widget projects a pound figure. Walk the signup and the third screen reads "Bliv customers report losing up to 20%+ of their body weight on GLP-1", followed by a full screen headed "Lose up to 20% of your body weight" and twenty-three named testimonials with pound counts. Semaglutide's phase 3 mean is about 14.9% over 68 weeks, so 20%+ reaches past the trial behind the molecule Bliv sells — and no cohort size, time point or method is published for the customer figure.
Where is Bliv's pricing page?
There isn't a separate one. /pricing, /faq and /semaglutide all resolve to the same single URL as the homepage, and the "Pricing" link in the navigation is an anchor to a section of the page you are already on. That page does now carry three plan cards: $116 a month for semaglutide, $199 for tirzepatide and $29 for pay-later financing, with a fourth figure — $58 — in the hero above them. Every one is hedged "as low as" and footnoted "based on plan structure and eligibility", and no plan length, dose band or renewal rate is attached to any of them. No price appears at any point inside the intake before the account gate.
Is Bliv really contract-free?
Its badge bar says "NO CONTRACTS" and its reasons block says "no hidden subscriptions". Its terms of service say "subscriptions include automatic recurring payments" and "will automatically renew for an additional period unless cancelled prior to the next billing period". Both are published. The refund policy is narrower than either badge suggests: a full refund only within 72 hours of purchase and only if medication has not gone to the pharmacy, $24.99 charged for a provider consultation, and — if a policy change stops Bliv supplying a medication — account credit rather than money back.
Does Bliv have an FDA warning letter?
Yes — letter 721479, issued to Bliv Wellness LLC on 20 February 2026, and still published on fda.gov when re-fetched on 26 August 2026. Its single finding, quoting the letter: the products pictured on the site identify Bliv on the label, suggesting Bliv is the compounder of those drugs when it is not. It says nothing about sterility, potency or contamination. A letter discloses; it does not disqualify.
Compare
Others selling what Bliv sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Bliv's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 1 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.